Health tech company MyFiziq (ASX: MYQ) has partnered with Canadian firm NuraLogix which will leverage the two company’s patented imaging technology. Using a smartphone camera, transdermal imaging and artificial intelligence (AI), the newly combined tech aims to determine a user’s probability of having COVID-19, as well as their risk of developing diseases that result in 70% of deaths globally.
The Memorandum of Understanding (MoU) brings together MyFiziq’s existing smartphone screening technology and NuraLogix’s Transdermal Optical Imaging (TOI™) to extract blood flow information from a user’s face after taking a 30-second selfie video.
Upon use of the non-invasive screening, users are provided with information about blood pressure, stress levels and heart rate amongst other parameters. Using this screening technology which is then processed by AI, the app can then offer an assessment on the user’s cardiovascular disease risk, diabetes risk and stroke risk which combine for 70% of global deaths annually.
“This is an extremely exciting partnership for the companies. Bringing our technologies together will not only create a one of a kind solution, furthermore it will be unrivalled. Our offerings in a standalone environment have a deep patent suite,” said MyFiziq CEO, Vlado Bosanac.
“When combining the company solutions, we form not only a unique offering, but one that enhances both companies’ ability to be the dominant player in digital health and convenience. The solutions form an easy to use, comprehensive review of an individual, accurately, privately, and conveniently from their mobile phone.
Beyond screening for the aforementioned disease risks, NuraLogix has been in collaboration with St. Michael’s Hospital, University of Toronto, and Zhongda Hospital in China to test symptom profiles of COVID-19 patients. Being developed into a smartphone app, NuraLogix is confident their imaging AI can determine the likelihood of a user having COVID-19 versus a seasonal flu or cold.
The app will initially be trialed by The Serfaty Clinic in Brazil and WeSure/WeFit in China before MyFiziq looks to broaden distribution globally.
Organisations around the world have been exploring the potential combination of thermal imaging cameras with drone technology to scan crowds as a measure in the fight against current and future pandemics.
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
Leave a Comment
You must be logged in to post a comment.